RxDoctor Payments Data

Amber Creel

Family · Franklinton, LANPI 1760859896

Payments from drug & device makers

$1,078in general payments, 2019–2025

Across 69 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$192
  • AstraZeneca$180
  • Novo Nordisk$124
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$117
  • Amgen$85
  • GSK$75
  • plus $304 from 14 others

What the payments were for

  • Food & beverage$1,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,078 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,479
Medicare patients
74
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$97,164
OzempicSemaglutide54$56,993
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$21,069
JardianceEmpagliflozin24$20,244
JanuviaSitagliptin Phosphate11$18,590
EliquisApixaban28$14,921
FarxigaDapagliflozin Propanediol17$10,706
Spiriva RespimatTiotropium Bromide20$9,921
Breo ElliptaFluticasone/Vilanterol14$5,415
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,147
SynthroidLevothyroxine Sodium13$987
Losartan Potassium93$751
Amlodipine Besylate180$710
Albuterol Sulfate HfaAlbuterol Sulfate33$701
Pantoprazole Sodium138$683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$17$97,16485 claims
Novo NordiskOzempic$124$56,99354 claims
AstraZenecaBreztri Aerosphere, Farxiga$180$31,77449 claims
Boehringer IngelheimJardiance, Spiriva Respimat$27$30,16544 claims
PfizerEliquis$47$14,92128 claims
GSKBreo Ellipta$75$5,41514 claims
AbbVieSynthroid$192$98713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.

Other family in Franklinton

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →